<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31655003</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>177</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Cu<sup>II</sup> (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease.</ArticleTitle><Pagination><StartPage>656</StartPage><EndPage>667</EndPage><MedlinePgn>656-667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.14881</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Diacetyl-bis(4-methyl-3-thiosemicarbazonato)copper<sup>II</sup> (Cu<sup>II</sup> (atsm)) ameliorates neurodegeneration and delays disease progression in mouse models of amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), yet the mechanism of action remains uncertain. Promising results were recently reported for separate Phase 1 studies in ALS patients and PD patients. Affected tissue in these disorders shares features of elevated Fe, low glutathione and increased lipid peroxidation consistent with ferroptosis, a novel form of regulated cell death. We therefore evaluated the ability of Cu<sup>II</sup> (atsm) to inhibit ferroptosis.</AbstractText><AbstractText Label="EXPERIMENTAL APPROACH">Ferroptosis was induced in neuronal cell models by inhibition of glutathione peroxidase-4 activity with RSL3 or by blocking cystine uptake with erastin. Cell viability and lipid peroxidation were assessed and the efficacy of Cu<sup>II</sup> (atsm) was compared to the known antiferroptotic compound liproxstatin-1.</AbstractText><AbstractText Label="KEY RESULTS">Cu<sup>II</sup> (atsm) protected against lipid peroxidation and ferroptotic lethality in primary and immortalised neuronal cell models (EC<sub>50</sub> : &#x2248;130 nM, within an order of magnitude of liproxstatin-1). Ni<sup>II</sup> (atsm) also prevented ferroptosis with similar potency, whereas ionic Cu<sup>II</sup> did not. In cell-free systems, Cu<sup>II</sup> (atsm) and Ni<sup>II</sup> (atsm) inhibited Fe<sup>II</sup> -induced lipid peroxidation, consistent with these compounds quenching lipid radicals.</AbstractText><AbstractText Label="CONCLUSIONS AND IMPLICATIONS">The antiferroptotic activity of Cu<sup>II</sup> (atsm) could therefore be the disease-modifying mechanism being tested in ALS and PD trials. With potency in vitro approaching that of liproxstatin-1, Cu<sup>II</sup> (atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis-related diseases.</AbstractText><CopyrightInformation>&#xa9; 2019 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Southon</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szostak</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7473-5283</Identifier><AffiliationInfo><Affiliation>School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acevedo</LastName><ForeName>Karla M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dent</LastName><ForeName>Krista A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volitakis</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belaidi</LastName><ForeName>Abdel A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crouch</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>Scott</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3479-2427</Identifier><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0001-8259-9069</Identifier><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>FightMND</Agency><Country>International</Country></Grant><Grant><Agency>Motor Neurone Disease Research Institute of Australia</Agency><Country>International</Country></Grant><Grant><GrantID>1103703</GrantID><Agency>National Health and Medical Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013882">Thiosemicarbazones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009942" MajorTopicYN="Y">Organometallic Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013882" MajorTopicYN="Y">Thiosemicarbazones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>A.I.B. is a shareholder in Prana Biotechnology Ltd, Cogstate Ltd, Brighton Biotech LLC, Grunbiotics Pty Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd. P.S.D. has served as a consultant to Collaborative Medicinal Development LLC. Collaborative Medicinal Development LLC has licensed intellectual property related to this subject from The University of Melbourne, where the inventors include P.S.D. and K.J.B.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31655003</ArticleId><ArticleId IdType="pmc">PMC7012947</ArticleId><ArticleId IdType="doi">10.1111/bph.14881</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard, P. A. , Cherny, R. A. , Finkelstein, D. I. , Gautier, E. , Robb, E. , Cortes, M. , &#x2026; Bush, A. I. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8&#x2010;hydroxy quinoline analogs is associated with decreased interstitial A&#x3b2;. Neuron, 59, 43&#x2013;55. 10.1016/j.neuron.2008.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.06.018</ArticleId><ArticleId IdType="pubmed">18614028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayton, S. , Fazlollahi, A. , Bourgeat, P. , Raniga, P. , Ng, A. , Lim, Y. Y. , &#x2026; Bush, A. I. (2017). Cerebral quantitative susceptibility mapping predicts amyloid&#x2010;&#x3b2;&#x2010;related cognitive decline. Brain, 140, 2112&#x2013;2119. 10.1093/brain/awx137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx137</ArticleId><ArticleId IdType="pubmed">28899019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayton, S. , Lei, P. , Hare, D. J. , Duce, J. A. , George, J. L. , Adlard, P. A. , &#x2026; Bush, A. I. (2015). Parkinson's disease iron deposition caused by nitric oxide&#x2010;induced loss of &#x3b2;&#x2010;amyloid precursor protein. The Journal of Neuroscience, 35, 3591&#x2013;3597. 10.1523/JNEUROSCI.3439-14.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3439-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605561</ArticleId><ArticleId IdType="pubmed">25716857</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraldo, H. , Boyd, L. P. , &amp; West, D. X. (1998). Copper(II) and nickel(II) complexes of glyoxaldehyde bis(N(3)&#x2010;substituted thiosemicarbazones). Transition Metal Chemistry, 23, 67&#x2013;71.</Citation></Reference><Reference><Citation>Cherubini, A. , Ruggiero, C. , Polidori, M. C. , &amp; Mecocci, P. (2005). Potential markers of oxidative stress in stroke. Free Radical Biology &amp; Medicine, 39, 841&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140205</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, I. Y. , Lee, P. , Statland, J. , McVey, A. , Dimachkie, M. , Brooks, W. , &amp; Barohn, R. (2015). Reduction in cerebral antioxidant, glutathione (GSH), in patients with ALS: A preliminary study. Neurology, 84(14 Supplement), P6.105.</Citation></Reference><Reference><Citation>Crouch, P. J. , Hung, L. W. , Adlard, P. A. , Cortes, M. , Lal, V. , Filiz, G. , &#x2026; Barnham, K. J. (2009). Increasing Cu bioavailability inhibits A&#x3b2; oligomers and &#x3c4; phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 106, 381&#x2013;386. 10.1073/pnas.0809057106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0809057106</ArticleId><ArticleId IdType="pmc">PMC2626711</ArticleId><ArticleId IdType="pubmed">19122148</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, M. J. , Alexander, S. , Cirino, G. , Docherty, J. R. , George, C. H. , Giembycz, M. A. , &#x2026; Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175, 987&#x2013;993. 10.1111/bph.14153</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14153</ArticleId><ArticleId IdType="pmc">PMC5843711</ArticleId><ArticleId IdType="pubmed">29520785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearling, J. L. , Lewis, J. S. , Mullen, G. E. , Welch, M. J. , &amp; Blower, P. J. (2002). Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure&#x2013;activity relationships. Journal of Biological Inorganic Chemistry, 7, 249&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">11935349</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexter, D. T. , Carter, C. J. , Wells, F. R. , Javoy&#x2010;Agid, F. , Agid, Y. , Lees, A. , &#x2026; Marsden, C. D. (1989). Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. Journal of Neurochemistry, 52, 381&#x2013;389. 10.1111/j.1471-4159.1989.tb09133.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1989.tb09133.x</ArticleId><ArticleId IdType="pubmed">2911023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, H. , Yan, C. Z. , Shi, H. , Zhao, Y. S. , Chang, S. Y. , Yu, P. , &#x2026; Duan, X. L. (2011). Hepcidin is involved in iron regulation in the ischemic brain. PLoS ONE, 6, e25324&#x2010;25333 10.1371/journal.pone.0025324</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025324</ArticleId><ArticleId IdType="pmc">PMC3177902</ArticleId><ArticleId IdType="pubmed">21957487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon, S. J. , Lemberg, K. M. , Lamprecht, M. R. , Skouta, R. , Zaitsev, E. M. , Gleason, C. E. , &#x2026; Stockwell, B. R. (2012). Ferroptosis: An iron&#x2010;dependent form of nonapoptotic cell death. Cell, 149, 1060&#x2013;1072. 10.1016/j.cell.2012.03.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId><ArticleId IdType="pmc">PMC3367386</ArticleId><ArticleId IdType="pubmed">22632970</ArticleId></ArticleIdList></Reference><Reference><Citation>Do Van, B. , Gouel, F. , Jonneaux, A. , Timmerman, K. , Gele, P. , Petrault, M. , &#x2026; Devedjian, J. C. (2016). Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiology of Disease, 94, 169&#x2013;178. 10.1016/j.nbd.2016.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.05.011</ArticleId><ArticleId IdType="pubmed">27189756</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly, P. S. , Caragounis, A. , Du, T. , Laughton, K. M. , Volitakis, I. , Cherny, R. A. , &#x2026; White, A. R. (2008). Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid&#x2010;&#x3b2; peptide. The Journal of Biological Chemistry, 283, 4568&#x2013;4577. 10.1074/jbc.M705957200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705957200</ArticleId><ArticleId IdType="pubmed">18086681</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, .A , Rowe, D. , Lee, W. , Noel, K. , &amp; Rosenfeld, C. (2019). Preliminary evidence of CuATSM treatment benefit in Parkinson's disease. In XXIV World Congress on Parkinson&#x2018;s Disease and Related Disorders. Montreal, Canada, pp 119&#x2013;120.</Citation></Reference><Reference><Citation>Friedmann Angeli, J. P. , Schneider, M. , Proneth, B. , Tyurina, Y. Y. , Tyurin, V. A. , Hammond, V. J. , &#x2026; Conrad, M. (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology, 16, 1180&#x2013;1191. 10.1038/ncb3064</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3064</ArticleId><ArticleId IdType="pmc">PMC4894846</ArticleId><ArticleId IdType="pubmed">25402683</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaschler, M. M. , Andia, A. A. , Liu, H. , Csuka, J. M. , Hurlocker, B. , Vaiana, C. A. , &#x2026; Stockwell, B. R. (2018). FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nature Chemical Biology, 14, 507&#x2013;515. 10.1038/s41589-018-0031-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-018-0031-6</ArticleId><ArticleId IdType="pmc">PMC5899674</ArticleId><ArticleId IdType="pubmed">29610484</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras, B. A. , Suprunchuk, T. , &amp; Bayley, C. H. (1962). The preparation of some thiosemicarbazones and their copper complexes. Canadian Journal of Chemistry, 40, 1053&#x2013;1059.</Citation></Reference><Reference><Citation>Grolez, G. , Moreau, C. , Danel&#x2010;Brunaud, V. , Delmaire, C. , Lopes, R. , Pradat, P. F. , &#x2026; Devos, D. (2016). The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: A systematic review. BMC Neurology, 16, 155&#x2013;171. 10.1186/s12883-016-0672-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-016-0672-6</ArticleId><ArticleId IdType="pmc">PMC5002331</ArticleId><ArticleId IdType="pubmed">27567641</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiney, S. J. , Adlard, P. A. , Bush, A. I. , Finkelstein, D. I. , &amp; Ayton, S. (2017). Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochemistry International, 104, 34&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">28082232</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad, A. Z. , Cronin, S. P. , Mashuta, M. S. , Buchanan, R. M. , &amp; Grapperhaus, C. A. (2017). Metal&#x2010;assisted ligand&#x2010;centered electrocatalytic hydrogen evolution upon reduction of a bis(thiosemicarbazonato)Cu(II) complex. Inorganic Chemistry, 56, 11254&#x2013;11265.</Citation><ArticleIdList><ArticleId IdType="pubmed">28857556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton, J. B. , Mercer, S. W. , Lim, N. K. , Faux, N. G. , Buncic, G. , Beckman, J. S. , &#x2026; Crouch, P. J. (2017). CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Scientific Reports, 7, 42292&#x2010;42302 10.1038/srep42292</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42292</ArticleId><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland, J. P. , Green, J. C. , &amp; Dilworth, J. R. (2006). Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Transactions, 783&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">16437173</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma, T. , Kobayashi, S. , Sato, H. , &amp; Fujii, J. (2019). Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. Experimental Cell Research, 384, 111592&#x2010;111600 10.1016/j.yexcr.2019.111592</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2019.111592</ArticleId><ArticleId IdType="pubmed">31479686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung, L. W. , Villemagne, V. L. , Cheng, L. , Sherratt, N. A. , Ayton, S. , White, A. R. , &#x2026; Barnham, K. J. (2012). The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. The Journal of Experimental Medicine, 209, 837&#x2013;854. 10.1084/jem.20112285</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112285</ArticleId><ArticleId IdType="pmc">PMC3328361</ArticleId><ArticleId IdType="pubmed">22473957</ArticleId></ArticleIdList></Reference><Reference><Citation>Huuskonen, M. T. , Tuo, Q. Z. , Loppi, S. , Dhungana, H. , Korhonen, P. , McInnes, L. E. , &#x2026; Kanninen, K. M. (2017). The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics, 14, 519&#x2013;532. 10.1007/s13311-016-0504-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0504-9</ArticleId><ArticleId IdType="pmc">PMC5398983</ArticleId><ArticleId IdType="pubmed">28050710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikawa, M. , Okazawa, H. , Kudo, T. , Kuriyama, M. , Fujibayashi, Y. , &amp; Yoneda, M. (2011). Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nuclear Medicine and Biology, 38, 945&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">21982566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikawa, M. , Okazawa, H. , Tsujikawa, T. , Matsunaga, A. , Yamamura, O. , Mori, T. , &#x2026; Yoneda, M. (2015). Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology, 84, 2033&#x2013;2039. 10.1212/WNL.0000000000001588</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001588</ArticleId><ArticleId IdType="pubmed">25904686</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner, P. , Dexter, D. T. , Sian, J. , Schapira, A. H. , &amp; Marsden, C. D. (1992). Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Annals of Neurology, 32(Suppl), S82&#x2013;S87. 10.1002/ana.410320714</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410320714</ArticleId><ArticleId IdType="pubmed">1510385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowol, C. R. , Reisner, E. , Chiorescu, I. , Arion, V. B. , Galanski, M. , Deubel, D. V. , &amp; Keppler, B. K. (2008). An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox noninnocent &#x3b1;&#x2010;N&#x2010;heterocyclic chalcogensemicarbazones. Inorganic Chemistry, 47, 11032&#x2013;11047.</Citation><ArticleIdList><ArticleId IdType="pubmed">18973290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal, P. K. , Saharan, S. , Tripathi, M. , &amp; Murari, G. (2015). Brain glutathione levels&#x2014;A novel biomarker for mild cognitive impairment and Alzheimer's disease. Biological Psychiatry, 78, 702&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">26003861</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaldan, S. , Bush, A. I. , Devos, D. , Rolland, A. S. , &amp; Moreau, C. (2018). Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. Free Radical Biology &amp; Medicine. 133, 221&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266679</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllum, E. J. , Lim, N. K. , Hickey, J. L. , Paterson, B. M. , Donnelly, P. S. , Li, Q. X. , &#x2026; Crouch, P. J. (2013). Therapeutic effects of CuII(atsm) in the SOD1&#x2010;G37R mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration, 14, 586&#x2013;590. 10.3109/21678421.2013.824000</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.824000</ArticleId><ArticleId IdType="pubmed">23952668</ArticleId></ArticleIdList></Reference><Reference><Citation>McCleverty, J. A. , &amp; Jones, C. J. (1970). Complexes of transition metals with Schiff bases and the factors influencing their redox properties. I. Nickel and copper complexes of some diketone bis&#x2010;thiosemicarbazones. Journal of the Chemical Society [Section] a: Inorganic, Physical, Theoretical, 2829&#x2013;2836.</Citation></Reference><Reference><Citation>Pap, E. H. , Drummen, G. P. , Winter, V. J. , Kooij, T. W. , Rijken, P. , Wirtz, K. W. , &#x2026; Post, J. A. (1999). Ratio&#x2010;fluorescence microscopy of lipid oxidation in living cells using C11&#x2010;BODIPY581/591 . FEBS Letters, 453, 278&#x2013;282. 10.1016/S0014-5793(99)00696-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(99)00696-1</ArticleId><ArticleId IdType="pubmed">10405160</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, U. J. , Lee, Y. A. , Won, S. M. , Lee, J. H. , Kang, S. H. , Springer, J. E. , &#x2026; Gwag, B. J. (2011). Blood&#x2010;derived iron mediates free radical production and neuronal death in the hippocampal CA1 area following transient forebrain ischemia in rat. Acta Neuropathologica, 121, 459&#x2013;473. 10.1007/s00401-010-0785-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0785-8</ArticleId><ArticleId IdType="pubmed">21120509</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyatigorskaya, N. , Sharman, M. , Corvol, J. C. , Valabregue, R. , Yahia&#x2010;Cherif, L. , Poupon, F. , &#x2026; Lehericy, S. (2015). High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Movement Disorders, 30, 1077&#x2013;1084. 10.1002/mds.26218</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26218</ArticleId><ArticleId IdType="pubmed">26011561</ArticleId></ArticleIdList></Reference><Reference><Citation>Raven, E. P. , Lu, P. H. , Tishler, T. A. , Heydari, P. , &amp; Bartzokis, G. (2013). Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. Journal of Alzheimer's Disease, 37, 127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23792695</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, T. T. , Pierce, W. M. , Markesbery, W. R. , &amp; Butterfield, D. A. (2009). Proteomic identification of HNE&#x2010;bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Research, 1274, 66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19374891</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, B. R. , Lim, N. K. , McAllum, E. J. , Donnelly, P. S. , Hare, D. J. , Doble, P. A. , &#x2026; Crouch, P. J. (2014). Oral treatment with CuII(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience, 34, 8021&#x2013;8031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe, D. , Mathers, S. , Smith, G. , Windebank, E. , Rogers, M. , Noel, K. , &amp; Rosenfeld, C. (2018). Modification of ALS disease progression in a phase 1 trial of CuATSM. Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration, 19(Suppl. S1), 280&#x2013;281.</Citation></Reference><Reference><Citation>Shah, R. , Margison, K. , &amp; Pratt, D. A. (2017). The potency of diarylamine radical&#x2010;trapping antioxidants as inhibitors of ferroptosis underscores the role of autoxidation in the mechanism of cell death. ACS Chemical Biology, 12, 2538&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">28837769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng, X. , Shan, C. , Liu, J. , Yang, J. , Sun, B. , &amp; Chen, D. (2017). Theoretical insights into the mechanism of ferroptosis suppression via inactivation of a lipid peroxide radical by liproxstatin&#x2010;1. Physical Chemistry Chemical Physics, 19, 13153&#x2013;13159.</Citation><ArticleIdList><ArticleId IdType="pubmed">28489094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sian, J. , Dexter, D. T. , Lees, A. J. , Daniel, S. , Agid, Y. , Javoy&#x2010;Agid, F. , &#x2026; Marsden, C. D. (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36, 348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080242</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson, E. P. , Henry, Y. K. , Henkel, J. S. , Smith, R. G. , &amp; Appel, S. H. (2004). Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology, 62, 1758&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Skouta, R. , Dixon, S. J. , Wang, J. , Dunn, D. E. , Orman, M. , Shimada, K. , &#x2026; Stockwell, B. R. (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. Journal of the American Chemical Society, 136, 4551&#x2013;4556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3985476</ArticleId><ArticleId IdType="pubmed">24592866</ArticleId></ArticleIdList></Reference><Reference><Citation>Soon, C. P. , Donnelly, P. S. , Turner, B. J. , Hung, L. W. , Crouch, P. J. , Sherratt, N. A. , &#x2026; Li, Q. X. (2011). Diacetylbis(N(4)&#x2010;methylthiosemicarbazonato) copper (II) (CuII(atsm)) protects against peroxynitrite&#x2010;induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. The Journal of Biological Chemistry, 286, 44035&#x2013;44044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243559</ArticleId><ArticleId IdType="pubmed">22033929</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockwell, B. R. , Friedmann Angeli, J. P. , Bayir, H. , Bush, A. I. , Conrad, M. , Dixon, S. J. , &#x2026; Zhang, D. D. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 171, 273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685180</ArticleId><ArticleId IdType="pubmed">28985560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao, Y. , Wang, Y. , Rogers, J. T. , &amp; Wang, F. (2014). Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: A systematic review and meta&#x2010;analysis. Journal of Alzheimer's Disease, 42, 679&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">24916541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi, H. , Abe, T. , Yamazaki, K. , Murata, T. , Ishizaki, E. , &amp; Isobe, C. (1999). Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neuroscience Letters, 260, 204&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10076903</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuo, Q. Z. , Lei, P. , Jackman, K. A. , Li, X. L. , Xiong, H. , Li, X. L. , &#x2026; Bush, A. I. (2017). &#x3c4;&#x2010;mediated iron export prevents ferroptotic damage after ischemic stroke. Molecular Psychiatry, 22, 1520&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira, F. G. , Hatzipetros, T. , Thompson, K. , Moreno, A. J. , Kidd, J. D. , Tassinari, V. R. , &#x2026; Gill, A. (2017). CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep, 2, 47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6084867</ArticleId><ArticleId IdType="pubmed">30135932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada, K. , Fujibayashi, Y. , Tajima, N. , &amp; Yokoyama, A. (1994). Cu&#x2010;ATSM, an intracellular&#x2010;accessible superoxide dismutase (SOD)&#x2010;like copper complex: Evaluation in an ischemia&#x2010;reperfusion injury model. Biological &amp; Pharmaceutical Bulletin, 17, 701&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920437</ArticleId></ArticleIdList></Reference><Reference><Citation>West, D. X. , Ives, J. S. , Bain, G. A. , Liberta, A. E. , Valdes&#x2010;Martinez, J. , Ebert, K. H. , &amp; Hernandez&#x2010;Ortega, S. (1997). Copper(II) and nickel(II) complexes of 2,3&#x2010;butanedione bis(N(3)&#x2010;substituted thiosemicarbazones). Polyhedron, 16, 1895&#x2013;1905.</Citation></Reference><Reference><Citation>Wong, B. X. , Ayton, S. , Lam, L. Q. , Lei, P. , Adlard, P. A. , Bush, A. I. , &amp; Duce, J. A. (2014). A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe2+ under physiologically relevant conditions. Biochimica et Biophysica Acta, 1840, 3299&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">25152357</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, Z. , Brose, J. , Schimo, S. , Ackland, S. M. , La Fontaine, S. , &amp; Wedd, A. G. (2011). Unification of the copper(I) binding affinities of the metallo&#x2010;chaperones Atx1, Atox1, and related proteins: Detection probes and affinity standards. The Journal of Biological Chemistry, 286, 11047&#x2013;11055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064159</ArticleId><ArticleId IdType="pubmed">21258123</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, H. , Perreau, V. M. , Dent, K. A. , Bush, A. I. , Finkelstein, D. I. , &amp; Adlard, P. A. (2016). Iron regulates apolipoprotein E expression and secretion in neurons and astrocytes. Journal of Alzheimer's Disease, 51, 471&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">26890748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, G. , Liang, Y. , Huang, Z. , Jones, D. W. , Pritchard, K. A. Jr. , &amp; Zhang, H. (2016). Inhibition of myeloperoxidase oxidant production by N&#x2010;acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke. Journal of Neuroinflammation, 13, 119&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879722</ArticleId><ArticleId IdType="pubmed">27220420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka, O. , Shah, R. , Li, B. , Friedmann Angeli, J. P. , Griesser, M. , Conrad, M. , &amp; Pratt, D. A. (2017). On the mechanism of cytoprotection by ferrostatin&#x2010;1 and liproxstatin&#x2010;1 and the role of lipid peroxidation in ferroptotic cell death. ACS Central Science, 3, 232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364454</ArticleId><ArticleId IdType="pubmed">28386601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>